FY2024 Earnings Estimate for CRSP Issued By Zacks Research

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Zacks Research upped their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings of ($5.20) per share for the year, up from their previous estimate of ($6.13). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.27) EPS, Q1 2025 earnings at ($1.51) EPS, Q2 2025 earnings at ($1.47) EPS, Q3 2025 earnings at ($1.37) EPS, Q4 2025 earnings at ($1.26) EPS, FY2025 earnings at ($5.61) EPS, Q1 2026 earnings at ($1.28) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.25) EPS and FY2026 earnings at ($2.24) EPS.

A number of other equities research analysts have also recently issued reports on the company. Barclays reduced their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Truist Financial decreased their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Needham & Company LLC reissued a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Rodman & Renshaw began coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 price target on the stock. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $74.94.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $50.84 on Thursday. The firm has a market cap of $4.34 billion, a P/E ratio of -17.96 and a beta of 1.67. CRISPR Therapeutics has a 52 week low of $43.42 and a 52 week high of $91.10. The firm’s 50-day simple moving average is $48.05 and its 200 day simple moving average is $51.69.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the previous year, the company earned ($1.41) earnings per share.

Institutional Trading of CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its stake in shares of CRISPR Therapeutics by 25.0% in the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares during the last quarter. FMR LLC raised its position in CRISPR Therapeutics by 1.0% in the third quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after purchasing an additional 23,075 shares during the last quarter. Vanguard Group Inc. raised its position in CRISPR Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 1,636,799 shares of the company’s stock valued at $111,564,000 after purchasing an additional 46,148 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of CRISPR Therapeutics by 3.6% during the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock valued at $47,383,000 after purchasing an additional 35,196 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of CRISPR Therapeutics by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 950,149 shares of the company’s stock valued at $51,326,000 after buying an additional 19,094 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at approximately $2,896,989.16. This trade represents a 1.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This represents a 13.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 35,382 shares of company stock valued at $1,917,679. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.